| 產(chǎn)品編號(hào) | bs-3524R-Gold |
| 英文名稱 | Rabbit Anti-PEA15/Gold Conjugated antibody |
| 中文名稱 | 膠體金標(biāo)記的星形膠質(zhì)細(xì)胞PEA15抗體 |
| 別 名 | Astrocytic phosphoprotein PEA 15; Astrocytic phosphoprotein PEA15; HMAT 1; HMAT1; Homolog of mouse MAT 1 oncogene; Homolog of mouse MAT1 oncogene; HUMMAT 1H; HUMMAT1H; MAT 1; MAT 1H; MAT1; MAT1H; PEA 15; PEA-15； PEA15 protein; PED; Phosphoprotein enriched in astrocytes 15; Phosphoprotein enriched in astrocytes 15kD; Phosphoprotein enriched in diabetes; PEA15_HUMAN. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說(shuō) 明 書(shū) | 100ul（10nm 15nm 35nm） |
| 研究領(lǐng)域 | 免疫學(xué) 神經(jīng)生物學(xué) 生長(zhǎng)因子和激素 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Dog, Rabbit, ) |
| 產(chǎn)品應(yīng)用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 15kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PEA15 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產(chǎn)品介紹 |
background: PED/PEA 15 (Phosphoprotein Enriched in Diabetes/Phosphoprotein Enriched in Astrocytes 15 kDa) is a widely expressed 15 kDa protein comprised of an N terminal region containing a canonical Death Effector Domain (DED) sequence and a nuclear export signal, and a C terminal region containing two serine phosphorylation sites. PED/PEA 15 has been implicated in the regulation of multiple cellular processes including apoptosis, integrin activation, and insulin sensitive glucose transport in insulin responsive cells. Phosphorylation of both serine 104 (a Protein Kinase C site) and serine 116 (a substrate of CaMKII and Akt) is required for PED/PEA 15 function. Function: Blocks Ras-mediated inhibition of integrin activationand modulates the ERK MAP kinase cascade. Inhibits RPS6KA3activities by retaining it in the cytoplasm (By similarity).Inhibits both TNFRSF6- and TNFRSF1A-mediated CASP8 activity andapoptosis. Regulates glucose transport by controlling both thecontent of SLC2A1 glucose transporters on the plasma membrane andthe insulin-dependent trafficking of SLC2A4 from the cell interiorto the surface. Subunit: Binds RPS6KA3, MAPK3 and MAPK1. Transient interactionwith PLD1 and PLD2 (By similarity). Interacts with CASP8 and FADD. Subcellular Location: Cytoplasm. Note=Associated withmicrotubules. Tissue Specificity: Ubiquitously expressed. Most abundant intissues such as heart, brain, muscle and adipose tissue whichutilize glucose as an energy source. Lower expression inglucose-producing tissues. Higher levels of expression are found intissues from individuals with type 2 diabetes than in controls. Post-translational modifications: Phosphorylated by protein kinase C andcalcium-calmodulin-dependent protein kinase. These phosphorylationevents are modulated by neurotransmitters or hormones. Similarity: Contains 1 DED (death effector) domain. Database links: Entrez Gene: 8682 Human Entrez Gene: 18611 Mouse Omim: 603434 Human SwissProt: Q15121 Human SwissProt: Q62048 Mouse Unigene: 517216 Human Unigene: 544 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
